ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting

    Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement

    Emmerik F.A. Leijten1,2, Tessa S. van Kempen1,2, Michel A.M. Olde Nordkamp1,2, Fleurieke H. Verhagen2,3, Sanne Hiddingh2,3, Jonas J.W. Kuiper2,3, Marianne L. Boes2,4 and Timothy R.D.J. Radstake1,2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…
  • Abstract Number: 1913 • 2017 ACR/ARHP Annual Meeting

    Inter-Omic Analysis Reveals Functional Relationship between Diverse Gut Microbiota and Dysregulated Host Immune Response in HLA-B27-Mediated Experimental Spondyloarthritis

    Tejpal Gill1, Stephen R. Brooks2, Mark Asquith3, James T. Rosenbaum4 and Robert Colbert5, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, 3Oregon Health & Science University, Portland, OR, 4Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, 5NIAMS/NIH, Bethesda, MD

    Background/Purpose: HLA-B27 has been hypothesized to alter gut microbiota and host-microbe interactions to promote spondyloarthritis (SpA). In HLA-B27 transgenic (HLA-B27 Tg) rats with experimental SpA,…
  • Abstract Number: 1914 • 2017 ACR/ARHP Annual Meeting

    Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease

    Zoya Qaiyum1,2, Eric Gracey3,4, Yuchen Yao3,4 and Robert D Inman5, 1Genetics and Development, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Immunology, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Immunology and Institute of Medical Science, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Ankylosing spondylitis (AS) has a strong connection with gut inflammation: 10% of AS patients have inflammatory bowel disease (IBD) and 60% have subclinical ileal…
  • Abstract Number: 1915 • 2017 ACR/ARHP Annual Meeting

    Gut-Derived TNF As Risk Factor for the Development of Sacroiliac Inflammation

    Karlijn Debusschere1, Heleen Cypers2, Peggy Jacques3, Filip van Den Bosch4, Thomas Renson5, Don Souza6, Martha Brown6, Gerald Nabozny7, Devin Dove6, Alexander Klimowicz8 and Dirk Elewaut9, 1Ghent University - VIB, Ghent, Belgium, 2Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Rheumatology, Ghent University Hospital, Gent, Belgium, 5Rheumatology, Ghent University Hospital, GENT, Belgium, 6Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 7[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 8Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 9VIB Inflammation Research Center, University of Ghent, Ghent, Belgium

    Background/Purpose: An intruiging link exists between gut and joint inflammation in spondyloarthritis (SpA). About 50% of patients has subclinical (eg. microscopic) gut inflammation, which represents…
  • Abstract Number: 1916 • 2017 ACR/ARHP Annual Meeting

    The Interferon Gamma Release Assay Is a Novel Predictor of Disease Activity in Systemic Lupus Erythematosus

    Jenna Thomason1, Christian Lood2 and Grant Hughes3, 1Medicine, University of Washington, Seattle, WA, 2Division of Rheumatology, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 3Medicine/Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Interferon gamma (IFN-G) is critical cytokine for defense against intracellular pathogens; it is also involved in the pathogenesis of systemic lupus erythematosus (SLE). The…
  • Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting

    A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)

    Yasser M El-Sherbiny1,2,3, Md Yuzaiful Md Yusof1, Antonios Psarras1, Elizabeth M.A. Hensor1, Kumba Kabba1, Alaa Mohamed1,4, Miriam Wittmann5, Paul Emery5,6 and Edward M Vital1,5,7, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, 3Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, 4Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 7University of Leeds, Leeds, United Kingdom

    Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
  • Abstract Number: 1918 • 2017 ACR/ARHP Annual Meeting

    Blood Levels of Complement Split Product iC3b and C3 Outperform Traditional Biochemical Measures of SLE Disease Activity in Associating with Active and Clinically Meaningful Changes

    Alfred Kim1, Deepali Sen2, Vibeke Strand3, Qiang John Fu4, Nancy Mathis1, Martin Schmidt5, Robin Bruchas6, Nick Staten6, Paul Olson6, Chad Stiening6 and John Atkinson1, 1Rheumatology, Washington University School of Medicine, Saint Louis, MO, 2Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, 3Stanford University, Palo Alto, CA, 4Biostatistics, Saint Louis University, Saint Louis, MO, 5Kypha, Inc., St. Louis, MO, 6Kypha, Inc., Saint Louis, MO

    Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
  • Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting

    The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity

    Chaim Putterman1, Michelle Petri2, Roberto Caricchio3, Jim C. Oates4, Pennina Safer5, Keren Jakobi-Brook5, Rachel Sorek5, Ilana Gluzman5, Steve Wallace6 and Irun R. Cohen5,7, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, 2Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 3Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, 4Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 5ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, 6ImmunArray Inc., VA, USA, Richmond, VA, 7Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel

    Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
  • Abstract Number: 1920 • 2017 ACR/ARHP Annual Meeting

    Tacrolimus Induces Remission in Refractory and Relapsing Lupus Nephritis By Decreasing P-Glycoprotein Expression and Function on Peripheral Blood Lymphocytes

    Vikas Gupta, Sukesh Edavalath, Mohit Kumar Rai, Harshit Singh, Saurabh Chaturvedi and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

     Background/Purpose: About 15-30% of Lupus Nephritis (LN) patients do not respond to first-line immunosuppressive therapy. P-glycoprotein (P-gp) mediated efflux of corticosteroids (CS) may contribute to…
  • Abstract Number: 1921 • 2017 ACR/ARHP Annual Meeting

    Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis

    Samar Soliman1,2, Fatma Mohamed3, Faten Ismail3, Ramesh Saxena4 and Chandra Mohan2, 1Rheumatology and rehabilitation, University of Minya, Minya, Egypt, 2Biomedical Engineering, University of Houston, Houston, TX, 3Rheumatology and Rehabilitation, University of Minya, Minya, Egypt, 4Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The goal of this study is to investigate how urinary angiostatin, VCAM-1 and established measures of renal function relate to specific histologic findings in…
  • Abstract Number: 1922 • 2017 ACR/ARHP Annual Meeting

    Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort

    Shervin Assassi1, Dinesh Khanna2, Monique Hinchcliff3, Virginia D. Steen4, Faye Hant5, Jessica K. Gordon6, Ami A. Shah7, Jun Ying8, William Swindell9, Wenjin Zheng10, Lisha Zhu10, Victoria K. Shanmugam11, Robyn T. Domsic12, Flavia V. Castelino13, Elana J. Bernstein14 and Tracy M. Frech15, 1University of Texas McGovern Medical School, Houston, TX, 2University of Michigan, Ann Arbor, MI, 3Rheumatology, Northwestern Medicine, Chicago, IL, 4Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 5Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Dermatology, University of Michigan - Ann Arbor, Ann Arbor, MI, 10University of Texas - School of Biomedical Informatics, Houston, TX, 11Rheumatology, The George Washington University, Washington, DC, 12Rheumatology, University of Pittsburgh, Pittsburgh, PA, 13Rheumatology, Harvard Medical School, Boston, MA, 14Rheumatology, Columbia University, New York, NY, 15Division of Rheumatology, University of Utah, Salt Lake City, UT

    Background/Purpose: To examine the global gene expression profile in patients with very early diffuse systemic sclerosis (SSc). Methods: Skin biopsies were obtained from patients enrolled…
  • Abstract Number: 1923 • 2017 ACR/ARHP Annual Meeting

    Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin

    Sokratis Apostolidis1, Giuseppina Stifano2, Tracy Tabib3, Lisa Rice2, Christina Morse3, Bashar Kahaleh4 and Robert A. Lafyatis3, 1Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Boston University School of Medicine, Boston, MA, 3Medicine, Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Medicine/Rheumatology, University of Toledo, Toledo, OH

    Background/Purpose: Vascular injury is a hallmark event in the pathogenesis of Systemic Sclerosis (SSc). Endothelial dysfunction happens early in the course of the disease and…
  • Abstract Number: 1924 • 2017 ACR/ARHP Annual Meeting

    The Nuclear Receptor ROR-Alpha As a Key Checkpoint of Tissue Repair

    Rosebeth Kagwiria1, Ruifang Liang2, Chih-Wei Chen3, Thomas Burris4, Georg Schett5 and Jörg Distler6, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, 5Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

    Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range…
  • Abstract Number: 1925 • 2017 ACR/ARHP Annual Meeting

    TGFβ Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy

    Ariella Zehender1, Neng-Yu Lin2, Adrian Stefanica3, Chih-Wei Chen4, Alina Soare5, Thomas Wohlfahrt6, Simon Rauber6, Christina Bergmann7, Andreas Ramming8, Oliver Distler9, Georg Schett10 and Jörg Distler5, 11Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 31Department of Internal Medicine 3 – Rheumatology and Immunology, University of Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 6Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 7Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 9Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 10Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Autophagy (Atg) is catabolic process allowing cells to degrade unnecessary or dysfunctional cellular organelles. Aberrant activation of Atg has been implicated into the pathogenesis…
  • Abstract Number: 1926 • 2017 ACR/ARHP Annual Meeting

    Cardiac Remodeling in Systemic Sclerosis: TGF-β/Fra2-Dependent Autophagy As a Novel Target for Heart Fibrosis

    Mara Stellato1, Michal Rudnik1, Florian Renoux1, Elena Pachera1, Karl Sotlar2, Karin Klingel3, Joerg C. Henes4, Przemyslaw Blyszczuk1,5, Oliver Distler1 and Gabriela Kania1, 1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Pathology, Ludwig Maximilians University, Munich, Germany, 3Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, 4Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 5Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland

    Background/Purpose: SSc patients frequently suffer from primary cardiac involvement. The main histological feature is fibrosis, but the mechanisms responsible for the heart failure remain unclear.…
  • « Previous Page
  • 1
  • …
  • 1331
  • 1332
  • 1333
  • 1334
  • 1335
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology